Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL2107 vs Keytruda for adjuvant therapy in resected non-small cell lung cancer
2024-519883-42-00Phase 3Authorised
- Sponsor
- Qilu Pharmaceutical
- Start
- Aug 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 15
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing QL2107 arm with Keytruda arm (2 arms). Primary endpoints: AUC tau,sd (Cycle 1) and AUC tau,ss (Cycle 7). Planned start Aug 2025; status: authorised.
02
Drugs
QL2107pembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-519883-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519883-42-00.